NASDAQ: CVRXCvrx Inc Stock
$15.26-0.45 (-2.86%)
Updated Apr 18, 2024
CVRX Price
$15.26
Fair Value Price
$19.64
Market Cap
$319.36M
52 Week Low
$9.08
52 Week High
$33.14
P/E
-7.67x
P/B
4.21x
P/S
16.61x
PEG
N/A
Dividend Yield
N/A
Revenue
$39.30M
Earnings
-$41.20M
Gross Margin
84.1%
Operating Margin
-99.89%
Profit Margin
-104.8%
Debt to Equity
0.52
Operating Cash Flow
-$39M
Beta
1.48
Next Earnings
Apr 25, 2024
Ex-Dividend
N/A
Next Dividend
N/A
CVRX Overview
CVRx, Inc. is a commercial-stage medical device company focused on neuromodulation solutions for patients with cardiovascular diseases. Its lead product, Barostim, is a pacemker-like device that improves symptoms for patients who have suffered heart failure. CVRx was incorporated in 2000 and is headquartered in Minneapolis, MN.
Zen Score
–
Industry Average (27)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how CVRX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
CVRX ($15.26) is undervalued by 22.32% relative to our estimate of its Fair Value price of $19.64 based on Discounted Cash Flow (DCF) modelling, but does not have a significant margin of safety
Below Fair Value Valuation
CVRX ($15.26) is significantly undervalued by 22.32% relative to our estimate of its Fair Value price of $19.64 based on Discounted Cash Flow (DCF) modelling, which includes a healthy margin of safety
Significantly Below Fair Value Valuation
CVRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
There are 30 more CVRX due diligence checks available for Premium users.
Be the first to know about important CVRX news, forecast changes, insider trades & much more!
CVRX News
Valuation
CVRX fair value
Fair Value of CVRX stock based on Discounted Cash Flow (DCF)
Price
$15.26
Fair Value
$19.64
Undervalued by
22.32%
CVRX ($15.26) is undervalued by... subscribe to Premium to read more.
Below Fair Value Valuation
CVRX ($15.26) is significantly undervalued... subscribe to Premium to read more.
Significantly Below Fair Value Valuation
CVRX is unprofitable, so we... subscribe to Premium to read more.
Below Benjamin Graham Formula Value Valuation
CVRX price to earnings (PE)
For valuing profitable companies with steady earnings
Company
-7.67x
Industry
28.61x
Market
41.33x
CVRX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
4.21x
Industry
3.63x
CVRX is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
CVRX's financial health
Profit margin
Revenue
$11.3M
Net Income
-$9.2M
Profit Margin
-81.1%
CVRX's cash burn is expected... subscribe to Premium to read more.
Interest Coverage Financials
CVRX's profit margin has increased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$115.2M
Liabilities
$39.3M
Debt to equity
0.52
CVRX's short-term assets ($112.09M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
CVRX's short-term assets ($112.09M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
CVRX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$7.8M
Investing
-$169.0k
Financing
$15.6M
CVRX's cash and short-term investments... subscribe to Premium to read more.
Debt Coverage Financials
CVRX vs Medical Device Stocks
Cvrx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.